CY1114912T1 - Εμβολιο για την προληψη της υποτροπης του καρκινου του μαστου - Google Patents
Εμβολιο για την προληψη της υποτροπης του καρκινου του μαστουInfo
- Publication number
- CY1114912T1 CY1114912T1 CY20141100076T CY141100076T CY1114912T1 CY 1114912 T1 CY1114912 T1 CY 1114912T1 CY 20141100076 T CY20141100076 T CY 20141100076T CY 141100076 T CY141100076 T CY 141100076T CY 1114912 T1 CY1114912 T1 CY 1114912T1
- Authority
- CY
- Cyprus
- Prior art keywords
- vaccine
- methods
- breast cancer
- inducing
- patient
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 4
- 206010006187 Breast cancer Diseases 0.000 title abstract 2
- 208000026310 Breast neoplasm Diseases 0.000 title abstract 2
- 230000001939 inductive effect Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000001681 protective effect Effects 0.000 abstract 2
- AHOKKYCUWBLDST-QYULHYBRSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s,3s)-2-[[(2s)-2,6-diaminohexanoyl]amino]-3-methylpentanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)[C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=CC=C1 AHOKKYCUWBLDST-QYULHYBRSA-N 0.000 abstract 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 abstract 1
- 108700020796 Oncogene Proteins 0.000 abstract 1
- 230000005867 T cell response Effects 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 102000046157 human CSF2 Human genes 0.000 abstract 1
- 210000002865 immune cell Anatomy 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/38—Antigens from snakes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4203—Receptors for growth factors
- A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/812—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/49—Breast
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94152407P | 2007-06-01 | 2007-06-01 | |
| EP08745615.8A EP2162149B1 (en) | 2007-06-01 | 2008-04-11 | Vaccine for the prevention of breast cancer relapse |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1114912T1 true CY1114912T1 (el) | 2017-01-25 |
Family
ID=40094045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20141100076T CY1114912T1 (el) | 2007-06-01 | 2014-01-30 | Εμβολιο για την προληψη της υποτροπης του καρκινου του μαστου |
Country Status (16)
| Country | Link |
|---|---|
| US (6) | US8222214B2 (enExample) |
| EP (2) | EP2722336A1 (enExample) |
| JP (6) | JP5635399B2 (enExample) |
| KR (5) | KR20210097209A (enExample) |
| CN (2) | CN105816867A (enExample) |
| AU (1) | AU2008260399C1 (enExample) |
| CA (1) | CA2687368C (enExample) |
| CY (1) | CY1114912T1 (enExample) |
| DK (1) | DK2162149T3 (enExample) |
| ES (1) | ES2445399T3 (enExample) |
| HR (1) | HRP20140102T1 (enExample) |
| MX (1) | MX2009012858A (enExample) |
| PL (1) | PL2162149T3 (enExample) |
| PT (1) | PT2162149E (enExample) |
| SI (1) | SI2162149T1 (enExample) |
| WO (1) | WO2008150577A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8945573B2 (en) | 2005-09-08 | 2015-02-03 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Targeted identification of immunogenic peptides |
| KR20210097209A (ko) * | 2007-06-01 | 2021-08-06 | 더 헨리 엠. 잭슨 파운데이션 포 더 어드벤스먼트 오브 밀리터리 메디신, 인코포레이티드 | 유방암 재발 예방용 백신 |
| EP2355843B8 (en) | 2008-12-10 | 2017-08-02 | The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | Vaccine for the prevention of breast cancer recurrence |
| CA2864841C (en) | 2012-02-17 | 2020-07-07 | Keith L. Knutson | Methods and materials for generating cd8+ t cells having the ability to recognize cancer cells expressing a her2/neu polypeptide |
| US10028918B2 (en) | 2012-05-08 | 2018-07-24 | Albert Einstein College Of Medicine, Inc. | Nanoparticle delivery vehicle for S-nitroso-N-acetyl cysteine and uses thereof |
| EP2854843A4 (en) | 2012-05-31 | 2016-06-01 | Sorrento Therapeutics Inc | ANTIGEN-BINDING PROTEINS FOR BINDING PD-L1 |
| US9180185B2 (en) | 2013-01-11 | 2015-11-10 | Hoffman-La Roche Inc. | Combination therapy of anti-HER3 antibodies |
| JP2014169283A (ja) * | 2013-02-05 | 2014-09-18 | Nitto Denko Corp | 粘膜投与用ワクチン組成物 |
| CN103961696A (zh) * | 2013-02-05 | 2014-08-06 | 日东电工株式会社 | 经皮给予用疫苗组合物 |
| EP2777711A1 (en) | 2013-03-11 | 2014-09-17 | Icon Genetics GmbH | Her2/Neu cancer vaccine |
| CN104513293A (zh) * | 2013-09-26 | 2015-04-15 | 深圳信立泰药业股份有限公司 | 一种多肽疫苗的盐及其制备方法和含有该盐的药物制品 |
| WO2015066020A1 (en) * | 2013-10-28 | 2015-05-07 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Methods of monitoring immune responses |
| US10434152B2 (en) * | 2014-02-20 | 2019-10-08 | Wayne State University | HER2 antigenic polypeptide compositions, and methods for their use in treatment and prevention of carcinomas |
| EA037855B1 (ru) | 2016-01-29 | 2021-05-27 | Сорренто Терапьютикс, Инк. | Полностью человеческое антитело класса igg, связывающееся с эпитопом pd-l1 |
| EP3463438B1 (en) * | 2016-05-31 | 2022-04-06 | The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | Vaccine therapy for treatment of endometrial and ovarian cancer |
| WO2020086412A1 (en) * | 2018-10-21 | 2020-04-30 | Slsg Limited Llc | Combination immunotherapy for treatment of triple-negative breast cancer |
| EP4336187A4 (en) | 2021-05-04 | 2025-06-11 | Aston Sci. Inc. | ANTI-HER2 VACCINE COMPOSITION |
| KR20230017640A (ko) | 2021-07-28 | 2023-02-06 | 주식회사 애스톤사이언스 | Her2 백신 조성물 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4744984A (en) | 1985-10-08 | 1988-05-17 | Vetrepharm Research, Inc. | Antiviral immunotherapeutic agent and preparation thereof |
| WO1990014357A1 (en) | 1989-05-19 | 1990-11-29 | Genentech, Inc. | Her2 extracellular domain |
| US7252829B1 (en) * | 1998-06-17 | 2007-08-07 | Idm Pharma, Inc. | HLA binding peptides and their uses |
| US5801005A (en) | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
| EP0793501A4 (en) | 1994-12-14 | 2000-05-03 | Scripps Research Inst | IN VIVO ACTIVATION OF TUMOR SPECIFIC CYTOTOXIC T CELLS |
| US6514942B1 (en) | 1995-03-14 | 2003-02-04 | The Board Of Regents, The University Of Texas System | Methods and compositions for stimulating T-lymphocytes |
| US20030022820A1 (en) | 1995-12-14 | 2003-01-30 | Linda A. Sherman | In vivo activation of tumor-specific cytotoxic t cells |
| US5891432A (en) | 1997-07-29 | 1999-04-06 | The Immune Response Corporation | Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same |
| WO2001008636A2 (en) * | 1999-08-03 | 2001-02-08 | The Ohio State University | Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein |
| EP1216055A2 (en) * | 1999-09-30 | 2002-06-26 | Corixa Corporation | Stress protein compositions and methods for prevention and treatment of cancer and infectious disease |
| US6602510B1 (en) | 2000-04-05 | 2003-08-05 | Epimmune Inc. | HLA class I A2 tumor associated antigen peptides and vaccine compositions |
| US20030224036A1 (en) | 1999-12-13 | 2003-12-04 | Fikes John D | Hla class I a2 tumor associated antigen peptides and vaccine compositions |
| US20070098776A1 (en) | 1999-12-13 | 2007-05-03 | Fikes John D | HLA class I A2 tumor associated antigen peptides and vaccine compositions |
| US20040121946A9 (en) * | 2000-12-11 | 2004-06-24 | John Fikes | Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions |
| US7037501B2 (en) * | 2001-01-04 | 2006-05-02 | Regents Of The University Of Minnesota | Myostatin immnoconjugate |
| AU2002318186A1 (en) * | 2001-07-03 | 2003-01-21 | Lexicon Genetics Incorporated | Novel human kielin-like proteins and polynucleotides encoding the same |
| AU2002354644C1 (en) | 2001-07-10 | 2009-04-30 | Corixa Corporation | Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres |
| US20030049253A1 (en) | 2001-08-08 | 2003-03-13 | Li Frank Q. | Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines |
| EP1482963A4 (en) | 2002-03-08 | 2010-06-09 | Univ Texas | CONTROLLED MODULATION OF THE AMINO ACID SIDE CHAIN LENGTH OF PEPTIDE ANTIGEN |
| KR100555211B1 (ko) * | 2002-07-16 | 2006-03-03 | 주식회사 팬제노믹스 | 항암효과를 갖는 Ｈｅｒ-２/ｎｅｕ ＤＮＡ 백신 |
| EP1553966B1 (en) * | 2002-10-03 | 2012-08-01 | Wyeth Holdings Corporation | Fusion peptides comprising the human papillomavirus e7 and e6 polypeptides and immunogenic compositions thereof |
| WO2004069866A1 (en) | 2003-02-10 | 2004-08-19 | Autogen Research Pty Ltd | Therapeutic molecules |
| JP2007524654A (ja) | 2003-06-06 | 2007-08-30 | エイジェニックス インコーポレイテッド | 癌ワクチン中のアジュバントとしてのラクトフェリン |
| WO2005014634A1 (en) * | 2003-08-12 | 2005-02-17 | Agt Biosciences Limited | A gene and uses therefor |
| US20050215501A1 (en) | 2003-10-24 | 2005-09-29 | Coley Pharmaceutical Group, Inc. | Methods and products for enhancing epitope spreading |
| US20060275777A1 (en) | 2005-06-03 | 2006-12-07 | Waelti Ernst R | Novel strategies for protein vaccines |
| KR20210097209A (ko) | 2007-06-01 | 2021-08-06 | 더 헨리 엠. 잭슨 파운데이션 포 더 어드벤스먼트 오브 밀리터리 메디신, 인코포레이티드 | 유방암 재발 예방용 백신 |
-
2008
- 2008-04-11 KR KR1020217023573A patent/KR20210097209A/ko not_active Abandoned
- 2008-04-11 ES ES08745615.8T patent/ES2445399T3/es active Active
- 2008-04-11 DK DK08745615.8T patent/DK2162149T3/da active
- 2008-04-11 MX MX2009012858A patent/MX2009012858A/es active IP Right Grant
- 2008-04-11 SI SI200831143T patent/SI2162149T1/sl unknown
- 2008-04-11 EP EP13191663.7A patent/EP2722336A1/en not_active Ceased
- 2008-04-11 WO PCT/US2008/060044 patent/WO2008150577A1/en not_active Ceased
- 2008-04-11 KR KR1020207004398A patent/KR102283639B1/ko not_active Expired - Fee Related
- 2008-04-11 PT PT87456158T patent/PT2162149E/pt unknown
- 2008-04-11 KR KR1020157007937A patent/KR101863534B1/ko not_active Expired - Fee Related
- 2008-04-11 CA CA2687368A patent/CA2687368C/en active Active
- 2008-04-11 CN CN201610201242.6A patent/CN105816867A/zh active Pending
- 2008-04-11 HR HRP20140102AT patent/HRP20140102T1/hr unknown
- 2008-04-11 CN CN200880018401A patent/CN101678093A/zh active Pending
- 2008-04-11 AU AU2008260399A patent/AU2008260399C1/en not_active Ceased
- 2008-04-11 JP JP2010510385A patent/JP5635399B2/ja not_active Expired - Fee Related
- 2008-04-11 PL PL08745615T patent/PL2162149T3/pl unknown
- 2008-04-11 KR KR1020187014920A patent/KR102079921B1/ko not_active Expired - Fee Related
- 2008-04-11 EP EP08745615.8A patent/EP2162149B1/en active Active
- 2008-04-11 US US12/602,214 patent/US8222214B2/en not_active Expired - Fee Related
- 2008-04-11 KR KR1020097027587A patent/KR101572474B1/ko not_active Expired - Fee Related
-
2012
- 2012-06-27 US US13/534,550 patent/US8796220B2/en active Active
-
2014
- 2014-01-30 CY CY20141100076T patent/CY1114912T1/el unknown
- 2014-07-04 JP JP2014138567A patent/JP6097724B2/ja not_active Expired - Fee Related
- 2014-07-09 US US14/327,224 patent/US9370560B2/en not_active Expired - Fee Related
-
2016
- 2016-10-28 JP JP2016211150A patent/JP2017071607A/ja active Pending
-
2018
- 2018-03-05 US US15/912,156 patent/US10842856B2/en not_active Expired - Fee Related
- 2018-08-16 JP JP2018153050A patent/JP7072467B2/ja not_active Expired - Fee Related
-
2020
- 2020-09-25 JP JP2020161232A patent/JP2021001218A/ja active Pending
- 2020-10-21 US US17/076,635 patent/US20220347281A1/en not_active Abandoned
-
2022
- 2022-01-12 US US17/574,178 patent/US20220241389A1/en not_active Abandoned
- 2022-04-18 JP JP2022068170A patent/JP2022095926A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1114912T1 (el) | Εμβολιο για την προληψη της υποτροπης του καρκινου του μαστου | |
| BR112021024966A2 (pt) | Composições e métodos para administração subcutânea de imunoterapia de câncer | |
| Vacchelli et al. | Trial watch: Peptide vaccines in cancer therapy | |
| CY1123526T1 (el) | Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενων ογκων των νευρωνων και του εγκεφαλου | |
| Wachowska et al. | 5-Aza-2′-deoxycytidine potentiates antitumour immune response induced by photodynamic therapy | |
| MX2010001086A (es) | Nueva inmunoterapia contra tumores neuronales y cerebrales. | |
| BR112016000810A2 (pt) | imunoterapia contra vários tumores tais como câncer de pulmão, incluindo cpcnp | |
| DK2102331T3 (da) | Anti-tumorvaccine afledt af normale kemisk modificerede CD4 -celler | |
| CY1110013T1 (el) | Συνδυασμοι για θεραπεια πολλαπλου μυελωματος | |
| CY1124950T1 (el) | Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων, οπως του καρκινου του πνευμονα συμπεριλαμβανομενου του μμκπ | |
| AR059982A1 (es) | Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano | |
| BR112016025035A2 (pt) | imunoterapia contra diversos tumores hematológicos, como a leucemia mieloide aguda (aml) | |
| MX2010001088A (es) | Composicion de peptidos asociados a tumor y vacunas relacionadas contra el cancer. | |
| EP2228072A4 (en) | CANCER VACCINE COMPOSITION | |
| NZ601677A (en) | Improved cancer therapy based on tumor associated antigens derived from cyclin d1 | |
| WO2012027379A3 (en) | Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines | |
| BRPI0510430A (pt) | composições e métodos para vacinação mucosal | |
| BRPI0408774A (pt) | vacinas de dna contra crescimento tumoral e seus usos | |
| MX2010002002A (es) | Peptido foxm1 y agente medicinal que lo contiene. | |
| CY1124812T1 (el) | Μεθοδος ανοσοενισχυτικης θεραπευτικης αντιμετωπισης του καρκινου | |
| Zhang et al. | Procyanidin, a kind of biological flavonoid, induces protective anti-tumor immunity and protects mice from lethal B16F10 challenge | |
| BR112013001946A2 (pt) | vírus varicela zoster inativado, composição farmacêutica, método para preparar um vírus varicela zoster inativado, vacina, e, método para o tratamento de herpes zoster em um indivíduo | |
| BRPI0820960B8 (pt) | composição, composição farmacêutica, e uso da composição | |
| EP4321218A3 (en) | Cancer stem cell targeted cancer vaccines | |
| CY1118486T1 (el) | Λαπατινιμπη για τη θεραπεια του καρκινου |